Across TCGA pan-cancer cohorts, BCAM mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BCAM data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher BCAM mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BCAM expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where BCAM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.302	0.916	.002	27	view →
PDAC	OS	Quartile	All	0.473	0.884	<.001	19	view →
CCRCC	DFS	Median	III,IV	0.865	0.523	.004	18	view →
HNSC	DFS	Median	IV	1.000	0.413	.033	4	view →
LSCC	DFS	Median	All	0.850	0.740	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: BCAM tumor-vs-normal RNA expression · all BCAM data types